Biomimix, Inc. (BMMX) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to Biomimix, Inc. (BMMX) stock?
Biomimix, Inc. (BMMX) no longer trades on public markets. The figures below are historical and are not a current quote.
Beta 1.04: the stock has moved about 4% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Biomimix, Inc. (BMMX). Biomimix, Inc. (BMMX) is a biotechnology company focused on developing innovative products inspired by natural biological processes. Sector: Industrials.
Last analyzed: Jun 14, 2026Analyst Coverage for BMMX: BMMX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BMMX against Industrials peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
BMMX: this read rests on a single discipline (Legends Council) — the other council disciplines have no scored data yet.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Biomimix, Inc. (BMMX) Industrial Operations Profile
Biomimix, Inc. (BMMX) leverages biomimicry to develop cutting-edge life science tools and services, focusing on innovative solutions for bone health and water treatment, positioning itself uniquely within the biotechnology sector.
What Is the Investment Thesis for BMMX?
Biomimix, Inc. presents a unique investment thesis driven by its innovative approach to biomimicry, which positions it within the growing biotechnology sector. Key value drivers include the increasing demand for advanced healthcare solutions, particularly in orthopedics, and the expanding market for eco-friendly water treatment technologies. The global biomaterials market, which encompasses products like Bonegrafix, is projected to grow significantly, offering substantial revenue potential. Additionally, the ongoing development of Medusa technology could unlock new revenue streams in the water treatment sector, which is becoming increasingly critical due to environmental regulations. However, investors should remain cautious of the inherent risks associated with trading on the OTC market, including lower liquidity and higher volatility compared to larger exchanges.
Based on FMP financials and quantitative analysis
BMMX Key Highlights
Market Cap: $0.00B, indicating a micro-cap status with potential for growth.
- Beta: 1.04, suggesting volatility in line with the market.
- Employee count: 1, highlighting a lean operational structure.
- Focus on biomimicry, which is a growing trend in biotechnology.
- Diverse product portfolio targeting both healthcare and environmental sectors.
Who Are BMMX's Competitors?
BMMX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AMGN Amgen Inc. | $382.47 | -2.25% | $206B | 815-pillar |
| GILD Gilead Sciences, Inc. | $144.81 | -0.58% | $180B | 635-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
| RCMT RCM Technologies, Inc. | $40.11 | +2.53% | $284M | 925-pillar |
| NNBR NN, Inc. | $3.56 | -3.26% | $294M | — |
| FIP FTAI Infrastructure Inc. | $3.30 | +0.30% | $390M | — |
| TRC Tejon Ranch Co. | $16.12 | -1.65% | $435M | 495-pillar |
| CRESY Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria | $12.61 | +5.79% | $818M | 455-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BMMX's Key Strengths?
Innovative product offerings based on biomimicry.
- Strong focus on R&D with potential for breakthrough technologies.
- Niche market positioning in the growing biotechnology sector.
What Are BMMX's Weaknesses?
Limited operational scale with only one employee.
- Low market capitalization indicating potential liquidity challenges.
- Dependence on successful R&D outcomes for growth.
What Could Drive BMMX Stock Higher?
Launch of new Bonegrafix products targeting the orthopedic market.
- Development of Medusa technology for water treatment applications.
- Expansion of ocean water-based skincare product line.
What Are the Key Risks for BMMX?
Regulatory hurdles affecting product development and market entry.
- Market competition from established biotechnology firms.
- Economic downturns impacting funding and investment in R&D.
What Are the Growth Opportunities for BMMX?
- Growth opportunity 1: The global biomaterials market is projected to reach $150 billion by 2026, driven by increasing demand for advanced medical solutions. Biomimix's Bonegrafix products, which enhance graft attributes for bone replacement, are well-positioned to capture a share of this expanding market, particularly as the aging population increases the prevalence of orthopedic conditions.
- Biomimix's ocean water-based skincare products align with this trend, offering potential for significant market penetration as consumers increasingly seek eco-friendly alternatives.
- Growth opportunity 3: The water treatment market is projected to grow to $700 billion by 2027, driven by stricter regulations and the need for sustainable solutions. Biomimix's Medusa technology, focusing on ballast water treatment and hydrogen production, positions the company to capitalize on this growing demand for innovative water treatment solutions.
- Growth opportunity 4: The bioprocess development sector is expanding, with a projected CAGR of 12% through 2025. Biomimix's expertise in bioprocess development could lead to partnerships with larger biotech firms, enhancing its market presence and revenue potential.
- Growth opportunity 5: As renewable energy technologies gain traction, the need for hydrogen production is increasing. Biomimix's focus on hydrogen production through its Medusa technology aligns with this trend, offering a pathway to tap into the renewable energy market, which is expected to grow significantly in the coming years.
What Threats Does BMMX Face?
- High volatility and liquidity risks associated with OTC market trading.
- Intense competition from established players in the biotechnology sector.
- Regulatory challenges in the healthcare and environmental sectors.
What Are BMMX's Competitive Advantages?
- Unique focus on biomimicry, differentiating its products from competitors.
- Proprietary technologies like Medusa provide a competitive edge in water treatment.
- Lean operational structure allows for agile decision-making and innovation.
What Does BMMX Do?
Founded in 1986, Biomimix, Inc. began its journey as C'watre International, Inc. and rebranded in April 2009 to reflect its focus on biomimicry—an approach inspired by nature's processes. Based in Ashburn, Virginia, the company operates primarily in the life sciences tools and services market, which encompasses genomics, proteomics, cell biology, analytical chemistry, bioprocess development, and bioinformatics. Biomimix's product offerings include Bonegrafix, a line of bioactive substances designed to enhance graft attributes for bone replacement and repair, addressing critical needs in orthopedic treatments. Additionally, the company has ventured into skincare with ocean water-based products aimed at promoting skin health. Biomimix is also engaged in the research and development of its Medusa technology, an innovative electro-chemical process targeting ballast water treatment, remote potable water treatment, and hydrogen production for renewable energy applications. This diverse portfolio reflects the company's commitment to harnessing nature-inspired solutions to meet contemporary challenges in health and environmental sustainability.
What Products and Services Does BMMX Offer?
- Develops biomimicry-inspired products for healthcare and environmental applications.
- Offers Bonegrafix products for bone replacement and repair.
- Creates ocean water-based skincare products to enhance skin health.
- Researches and develops Medusa technology for innovative water treatment solutions.
- Focuses on bioprocess development and bioinformatics services.
How Does BMMX Make Money?
- Generates revenue through the sale of innovative healthcare and skincare products.
- Engages in research and development partnerships with other biotech firms.
- Explores licensing opportunities for proprietary technologies.
What Industry Does BMMX Operate In?
The biotechnology sector is witnessing rapid growth, driven by advancements in life sciences and an increasing focus on sustainable solutions. As environmental concerns rise, technologies like those developed by Biomimix, particularly in water treatment, are gaining traction. The competitive landscape includes various players in the life sciences space, but Biomimix's unique focus on biomimicry sets it apart, providing a niche that could be strategically advantageous.
Who Are BMMX's Key Customers?
- Healthcare providers seeking advanced orthopedic solutions.
- Consumers interested in natural and sustainable skincare products.
- Government and industrial clients requiring water treatment solutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 46 |
| 2026-08-24 | 46 |
| 2026-08-25 | 46 |
| 2026-08-26 | 46 |
What changed?
The score has stayed at 46.
Over the same 3 days the stock moved +0.0%.
Company Profile
Biomimix, Inc. operates in the Conglomerates industry within the Industrials sector. The company is led by CEO Jeff Conroy. BMMX has traded publicly since 2000.
BMMX Financials
Bull Case vs Bear Case
Bull Case
- Innovative product offerings based on biomimicry.
- Strong focus on R&D with potential for breakthrough technologies.
- Niche market positioning in the growing biotechnology sector.
- Upcoming: Launch of new Bonegrafix products targeting the orthopedic market.
Bear Case
- Limited operational scale with only one employee.
- Low market capitalization indicating potential liquidity challenges.
- Dependence on successful R&D outcomes for growth.
- Potential: Regulatory hurdles affecting product development and market entry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
BMMX Latest News
No recent news available for BMMX.
Leadership: Jeff Conroy
CEO
Jeff Conroy has been leading Biomimix, Inc. since its inception in 1986, guiding the company through its evolution from C'watre International, Inc. to its current focus on biomimicry. With a background in biotechnology and business management, he has a deep understanding of the industry and has been instrumental in shaping the company's strategic direction.
Track Record: Under Jeff's leadership, Biomimix has developed a unique product portfolio that addresses critical needs in healthcare and environmental sustainability. His commitment to innovation has positioned the company as a niche player in the biotechnology sector.
BMMX OTC Market Information
The OTC Other tier represents companies that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. These stocks often have lower liquidity and higher volatility, making them riskier investments compared to those listed on larger exchanges.
- OTC Tier: OTC Other
- Lower liquidity compared to stocks listed on major exchanges.
- Increased volatility and price fluctuations.
- Potential lack of transparency in financial reporting.
- Verify the company's financial health through available reports.
- Assess the management team's experience and track record.
- Monitor industry trends and market positioning.
- Evaluate product development timelines and milestones.
- Check for any regulatory compliance issues.
- Established history since 1986, indicating longevity.
- Focus on innovative biomimicry, aligning with market trends.
- Engagement in R&D suggests commitment to growth and development.
Common Questions About BMMX (Industrials)
What happened to Biomimix, Inc. (BMMX) stock?
Biomimix, Inc. (BMMX) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy BMMX shares?
No. BMMX stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for BMMX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before BMMX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Biomimix, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Biomimix, Inc. do?
Biomimix, Inc. develops and commercializes innovative products inspired by biomimicry, focusing on healthcare solutions like Bonegrafix for bone repair and ocean water-based skincare products.
What are the main risks for BMMX?
Biomimix, Inc. faces several risks, including regulatory hurdles that could impact product development timelines and market entry. Additionally, the company operates in a competitive landscape dominated by larger biotechnology firms, which may pose challenges in gaining market share. The inherent volatility of trading on the OTC market also presents liquidity risks.
How does Biomimix, Inc. compare to competitors in its industry?
Biomimix, Inc. differentiates itself through its unique focus on biomimicry, setting it apart from traditional biotechnology firms like Amgen and Gilead Sciences.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial disclosures available due to OTC classification.